Arcellx Inc (ACLX)
NASDAQ:ACLX
ACLX Stock Chart & Stats
$114.89
-$3.36(-4.36%)
At close: 4:00 PM EST
$114.89
-$3.36(-4.36%)
Day’s Range― - ―
52-Week Range$47.86 - $114.94
Previous CloseN/A
Volume227.93K
Average Volume (3M)1.23M
Market Cap
$6.72B
Enterprise Value$6.73B
Total Cash (Recent Filing)$450.33M
Total Debt (Recent Filing)$96.26M
Price to Earnings (P/E)―
Beta0.79
Next Earnings
May 07, 2026EPS Estimate
-1.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.00
Shares Outstanding58,479,813
10 Day Avg. Volume719,782
30 Day Avg. Volume1,232,962
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)9.12
Price to Sales (P/S)164.73
P/FCF Ratio-17.27
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue302.20
Enterprise Value/Gross Profit-466.30
Enterprise Value/Ebitda-34.02
Forecast
1Y Price Target
$112.85Price Target Upside-1.78% Downside
Rating ConsensusHold
Number of Analyst Covering16
EPS Forecast (FY)-3.71
Revenue Forecast (FY)$73.66M
Bulls Say, Bears Say
Bulls Say
Regulatory Pathway ClarityRegulatory acceptance of anito-cel's biologics application with an assigned standard review reduces regulatory uncertainty and creates a clear pathway toward approval and market entry.
Strategic Fit And ManufacturingGilead's established cell therapy experience and manufacturing capabilities position the buyer to maximize anito-cel's launch and scale production efficiently, supporting commercialization execution.
Therapeutic Differentiation And SafetyAnito-cel's D-domain binder showed lower antigen-independent activation and a favorable safety profile in tests, indicating potentially reduced neurotoxicity and a competitive advantage versus current CAR-T options.
Bears Say
Contingent Payment UncertaintyAnalyst highlights that a contingent payment in the transaction depends on ambitious cumulative sales milestones, creating uncertainty about whether shareholders will receive significant additional value beyond the cash component.
Deal Execution Risk From Contract TermsThe acquisition agreement contains a material adverse effect clause that could allow the buyer to abandon the deal if anito-cel faces commercial, regulatory, clinical, or manufacturing setbacks, introducing execution risk for the transaction.
Valuation Capped By Acquisition OfferAnalyst notes the acquisition offer effectively sets a takeover price for Arcellx, causing the stock to trade at deal value and limiting potential upside for shareholders.
Arcellx Inc News
ACLX FAQ
What was Arcellx Inc’s price range in the past 12 months?
Arcellx Inc lowest stock price was $47.86 and its highest was $114.94 in the past 12 months.
What is Arcellx Inc’s market cap?
Arcellx Inc’s market cap is $6.72B.
When is Arcellx Inc’s upcoming earnings report date?
Arcellx Inc’s upcoming earnings report date is May 07, 2026 which is in 21 days.
How were Arcellx Inc’s earnings last quarter?
Arcellx Inc released its earnings results on Feb 26, 2026. The company reported -$1.003 earnings per share for the quarter, beating the consensus estimate of -$1.047 by $0.044.
Is Arcellx Inc overvalued?
According to Wall Street analysts Arcellx Inc’s price is currently Overvalued.
Does Arcellx Inc pay dividends?
Arcellx Inc does not currently pay dividends.
What is Arcellx Inc’s EPS estimate?
Arcellx Inc’s EPS estimate is -1.11.
How many shares outstanding does Arcellx Inc have?
Arcellx Inc has 58,479,813 shares outstanding.
What happened to Arcellx Inc’s price movement after its last earnings report?
Arcellx Inc reported an EPS of -$1.003 in its last earnings report, beating expectations of -$1.047. Following the earnings report the stock price went up 0.105%.
Which hedge fund is a major shareholder of Arcellx Inc?
Currently, no hedge funds are holding shares in ACLX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Arcellx Inc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$112.85 (-1.78% Downside)
$112.85 (-1.78% Downside)
Blogger Sentiment
Bullish
ACLX Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 2.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 4.6%
Last 30 Days ▼ 4.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
90.53%
12-Months-Change
Fundamentals
Return on Equity
-55.42%
Trailing 12-Months
Asset Growth
-15.09%
Trailing 12-Months
Company Description
Arcellx Inc
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.
ACLX Stock 12 Month Forecast
Average Price Target
$112.85
▼(-1.78% Downside)
Technical Analysis
Protagonist Therapeutics
―
Apellis Pharmaceuticals
―
Immunovant
―
Beam Therapeutics
―
MoonLake Immunotherapeutics
―
Ownership Overview
Currently, No data available
---